Ann: Promising New Data in 1st line NSCLC from INSIGHT-003 Trial, page-3

Seems to be a well confirmed pattern now in Efti trials with Keytruda . It roughly doubles the response rate and OS.
Maybe Efti will find a killer app where it cleans up cancer
in a particular indication like Keytruda. But for now, doubling Keytruda efficacy appears to be what we are looking at. That will improve no doubt with experience.

So what value do you put on that? Will it double efficacy of a large range of treatments?..Maybe.

Hard to know the value unless you are BP insider with a finger on the pulse of all relevant trials. But I’m not aware of anything else doing so much with no side effects low cost of goods and ease of treatment.

Surely BP can’t leave Immutep hanging out in the wind for much longer.